Life Technologies Corp. (NASDAQ:LIFE) fell 5.38% to $42.75 after the he Carlsbad, California-based company’s second-quarter net income attributable to controlling interest was $110.6 million or $0.58 per share, compared to $39.0 million or $0.22 per share in the prior-year quarter.
On a non-GAAP basis, net income rose to $174.6 million or $0.91 per share from $141.2 million or $0.79 per share a year ago.
On average, 16 analysts polled by Thomson Reuters expected the company to post earnings of $0.87 per share. Analysts’ estimates typically exclude special items.
Charles River Laboratories (NYSE:CRL) lost 5.50% to $32.05 on high volume of 1.59 million shares. Charles River Laboratories International, Inc. is a global provider of solutions that advance the drug discovery and development process, including research models and associated services, and outsourced pre-clinical services.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) soared 24% to $1.34 after it announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson’s disease psychosis (PDP).
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) climbed 10% to $10.01 after it reported net income for the second quarter of $9.3 million or $0.14 per share, flat with last year quarter.
Net sales were $28.3 million for the quarter, up from $25.3 million in the previous year quarter.
One Comment for “Hot Biotech Stock Movers (LIFE, CRL, ACAD, QCOR)”